Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
143.81
-1.50 (-1.03%)
At close: Oct 1, 2026, 4:00 PM EDT
144.92
+1.11 (0.77%)
Pre-market: Oct 2, 2026, 7:48 AM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $16.61B in the quarter ending June 30, 2026, with 5.07% growth. This brings the company's revenue in the last twelve months to $66.57B, up 4.64% year-over-year. In the year 2025, Merck & Co. had annual revenue of $65.01B with 1.31% growth.
Revenue (ttm)
$66.57B
Revenue Growth
+4.64%
P/S Ratio
5.33
Revenue / Employee
$887,587
Employees
75,000
Market Cap
354.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.01B | 843.00M | 1.31% |
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Eli Lilly and Company | 79.67B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
MRK News
- 1 day ago - Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 - Business Wire
- 1 day ago - Merck says experimental skin disease drug meets main goal in mid-stage study - Reuters
- 1 day ago - Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) - Business Wire
- 3 days ago - US drugmakers turn to China for licensing deals - Reuters
- 4 days ago - Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
- 4 days ago - Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor - Business Wire
- 6 days ago - Merck, Daiichi Sankyo withdraw US application for lung cancer drug - Reuters
- 6 days ago - Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn - Business Wire